Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein. BNT162b2 is highly efficacious against coronavirus disease 2019 (Covid-19) and is currently approved, conditionally approved, or authorized for emergency use worldwide. At the time of initial authorization, data beyond 2 months after vaccination were unavailable. METHODS: In an ongoing, placebo-controlled, observer-blinded, multinational, pivotal efficacy trial, we randomly assigned 44,165 participants 16 years of age or older and 2264 participants 12 to 15 years of age to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. The trial end points were vaccine efficacy against laboratory-confirmed Covid-19 and safety, which were both evaluated through 6 months after vaccination. RESULTS: BNT162b2 continued to be safe and have an acceptable adverse-event profile. Few participants had adverse events leading to withdrawal from the trial. Vaccine efficacy against Covid-19 was 91.3% (95% confidence interval [CI], 89.0 to 93.2) through 6 months of follow-up among the participants without evidence of previous SARS-CoV-2 infection who could be evaluated. There was a gradual decline in vaccine efficacy. Vaccine efficacy of 86 to 100% was seen across countries and in populations with diverse ages, sexes, race or ethnic groups, and risk factors for Covid-19 among participants without evidence of previous infection with SARS-CoV-2. Vaccine efficacy against severe disease was 96.7% (95% CI, 80.3 to 99.9). In South Africa, where the SARS-CoV-2 variant of concern B.1.351 (or beta) was predominant, a vaccine efficacy of 100% (95% CI, 53.5 to 100) was observed. CONCLUSIONS: Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, these clinical trials only included cases of the original and alpha variants and did not include the latter variants such as Delta and Omicron.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy of the vaccine at preventing COVID-19 infection in individuals aged 16 was 95%, and over the six subsequent months, vaccine efficacy was 91.3%.385–387”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [386]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“protection against infection starts to wane within a few months of administration.8–11”
From Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among the studies with longer follow-up, Thomas et al. [28] and El Sahly et al. [29] reported mRNA vaccine efficacy of 91–93% against laboratory-confirmed SARS-CoV-2 infection and 97–98% against severe disease.”
From Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024 (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredIn the citing paper
“Vaccine efficacy against Covid-19 from 7 days to 6 months after the second dose was 91%,6 with a similar estimated real-world effectiveness from 8 to 28 days after the second dose.7”
From Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationBNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citation
Cited by
Items 201–300 of 1,004
Baum, U., Poukka, E., Leino, T., Kilpi, T., Nohynek, H., & Palmu, A. A. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07814-4 · Cited by 46
Oktay, E., Alem, F., Hernandez, K. R., Girgis, M. J., Green, C. M., Mathur, D., Medintz, I. L., Narayanan, A., & Veneziano, R. (2023) · Communications Biology · doi:10.1038/s42003-023-04689-2 · Cited by 47
Haroz, E. E., Kemp, C. G., O’Keefe, V. M., Pocock, K., Wilson, D. R., Christensen, L., Walls, M. L., Barlow, A., & Hammitt, L. L. (2022) · American Journal of Public Health · doi:10.2105/ajph.2021.306635 · Cited by 49
Self-citationServellita, V., Morris, M. K., Sotomayor-González, A., Gliwa, A. S., Torres, E., Brazer, N., Zhou, A. Y., Hernandez, K., Sankaran, M., Wang, B., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01041-4 · Cited by 48
Spike protein of SARS-CoV-2 variants: a brief review and practical implications
Candido, K. L., Eich, C. R., de Fariña, L. O., Kadowaki, M. K., Silva, J. L. D. C., Maller, A., & Simão, R. D. C. G. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00743-z · Cited by 50
Chrissian, A. A., Oyoyo, U. E., Patel, P., Beeson, W. L., Loo, L. K., Tavakoli, S., & Dubov, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.046 · Cited by 46
Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer
Figueiredo, J. C., Merin, N. M., Hamid, O., Choi, S. Y., Lemos, T., Cozen, W., Nguyen, N., Finster, L. J., Foley, J., Darrah, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-3554 · Cited by 48
Piechotta, V., Mellinghoff, S. C., Hirsch, C., Brinkmann, A., Iannizzi, C., Kreuzberger, N., Adams, A., Monsef, I., Stemler, J., Cornely, O. A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00684-8 · Cited by 48
Rafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2023) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2023.0160 · Cited by 45
Hou, J., Wei, Y., Zou, J., Jaffery, R., Sun, L., Liang, S., Zheng, N., Guerrero, A. M., Egan, N. A., Bohat, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44175-1 · Cited by 47
Yanir, Y., Doweck, I., Shibli, R., Najjar‐Debbiny, R., & Saliba, W. (2022) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2021.4278 · Cited by 49
Du, Y., Chen, L., & Shi, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.829176 · Cited by 46
“In addition to six included RCTs, a comprehensive search identified three relevant trials (20, 39, 40) that included adolescents, all of which confirmed good safety and immunogenicity of the vaccine in this age group but were not included in the review because no information was specifically provided for specific age…”
BackgroundComparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis
Sutton, N., Ramos, A. S. F., Beales, E. R., Smith, D., Ikram, S., Galiza, E. P., Hsia, Y., & Heath, P. T. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2098719 · Cited by 46
“Seven papers were excluded from the meta-analysis: four [21–24] due to a high risk of bias and three [25–27] due to missing data which was not available from the authors.”
BackgroundBenn, C. S., Schaltz‐Buchholzer, F., Nielsen, S., Netea, M. G., & Aaby, P. (2023) · iScience · doi:10.1016/j.isci.2023.106733 · Cited by 50
The Impact of the COVID-19 Vaccine Distribution on Mental Health Outcomes
Agrawal, V., Cantor, J., Sood, N., & Whaley, C. (2021) · National Bureau of Economic Research · doi:10.3386/w29593 · Cited by 45
Kayano, T., Sasanami, M., Kobayashi, T., Ko, Y. K., Otani, K., Suzuki, M., & Nishiura, H. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100571 · Cited by 44
Fusco, M. D., Marczell, K., Deger, K. A., Moran, M. M., Wiemken, T. L., Cane, A. D., de Boisvilliers, S., Yang, J., Vaghela, S., & Roïz, J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2071427 · Cited by 46
Syenina, A., Gan, E. S., Toh, J. Z. N., de Alwis, R., Lin, L. Z., Tham, C. Y. L., Yee, J. X., Leong, Y. S., Sam, H., Cheong, C., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001643 · Cited by 47
Hamm, S. R., Møller, D. L., Pérez‐Alós, L., Hansen, C. B., Pries‐Heje, M. M., Heftdal, L. D., Hasselbalch, R. B., Fogh, K., Madsen, J. R., Armenteros, J. J. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832501 · Cited by 46
SARS‐CoV‐2 Omicron and its current known unknowns: A narrative review
Le, T. T. B., Vasanthakumaran, T., Hau, N. T. H., Hung, I., Luu, M. N., Khan, Z. A., An, N. T., Tran, V. P., Lee, W. J., Aziz, J. M. A., et al. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2398 · Cited by 45
“According to Pfizer, the fully 2‐ dose Pfizer vaccination can provide more than 80% safeguard against severe illness and mortality for 6 months; the booster dose aids in increasing protection by 10%; exceptionally, this may still be effective with Omicron infections.(73) Even though the significant reduction of the ne…”
BackgroundCOVID-19 Vaccines, Effectiveness, and Immune Responses
Abufares, H. I., Alsoud, L. O., Alqudah, M. A. Y., Shara, M., Soares, N. C., Alzoubi, K. H., El‐Huneidi, W., Bustanji, Y. K., Soliman, S. S. M., & Semreen, M. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315415 · Cited by 51
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Du, L., Yang, Y., Zhang, X., & Li, F. (2021) · Nanoscale · doi:10.1039/d1nr03831a · Cited by 45
Tomkins‐Netzer, O., Sar, S., Barnett‐Griness, O., Friedman, B., Shyriaieva, H., & Saliba, W. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.05.015 · Cited by 43
COVID-19 in Latin America: A Snapshot in Time and the Road Ahead
LaRotta, J., Escobar, O., Avila-Aguero, M. L., Torres, J. P., de Almeida, R. S., Morales, G. D. C., & Srivastava, A. K. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00748-z · Cited by 49
“2% in participants from Argentina and Brazil, respectively [93].”
Background(2022) · doi:10.1186/s12916-022-02480-4 · Cited by 43
Palmer, C. D., Scallan, C. D., Kraemer Tardif, L. D., Kachura, M. A., Rappaport, A. R., Koralek, D. O., Uriel, A., Gitlin, L., Klein, J., Davis, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39053-9 · Cited by 42
“Currently authorized vaccines played an important and successful role in reducing the mortality and morbidity associated with COVID-19 3,4,36 , but the rapid dissemination of new VOC 36,37 and relatively short durability in humoral response of authorized vaccines 5,38 – 42 necessitates continued…”
Coppeta, L., Ferrari, C., Somma, G., Mazza, A., D’Ancona, U., Marcuccilli, F., Grelli, S., Aurilio, M. T., Pietroiusti, A., Magrini, A., et al. (2022) · Vaccines · doi:10.3390/vaccines10020141 · Cited by 43
“To date, detectable levels of antiviral antibodies have persisted for up to 8 months after acute SARS-CoV-2 infection and up to 6 months after completion of the two-dose mRNA vaccine regimen [16].”
BackgroundOral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19
Hammond, J., Yunis, C., Fountaine, R. J., Luscan, G., Burr, A. M., Zhang, W., Wisemandle, W., Soares, H. D., Baniecki, M. L., Hendrick, V. M., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309002 · Cited by 44
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 47
“Among them, seven studies (41, 44, 46, 50, 59, 108, 109) were excluded from the overall analysis because their samples overlapped with another four studies (33, 34, 43, 56).”
ResultA novel mRNA vaccine, SYS6006, against SARS-CoV-2
Xu, K., Lei, W., Kang, B., Yang, H., Wang, Y., Lu, Y., Lv, L., Sun, Y., Zhang, J., Wang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1051576 · Cited by 42
“The most common adverse effects included headache, joint pain, muscle pain, fatigue, fever, pain and swelling at the injection site, which were entirely tolerable (6, 7).”
BackgroundMethodBroad-spectrum pan-genus and pan-family virus vaccines
Tan, C. W., Valkenburg, S., Poon, L. L. M., & Wang, L. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.05.017 · Cited by 44
Lind, M. L., Dorión, M., Houde, A. J., Lansing, M., Lapidus, S., Thomas, R., Yildirim, I. B., Omer, S. B., Schulz, W. L., Andrews, J. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40750-8 · Cited by 43
Liang, X., Xu, Q., Jia, Z.-J., Wu, M., Liu, Y., Lin, L., Liu, L., & Yang, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876037 · Cited by 45
Kaabi, N. A., Oulhaj, A., Ganesan, S., Hosani, F. I. A., Najim, O., Ibrahim, H., Acuna, J. M., Alsuwaidi, A. R., Kamour, A. M., Alzaabi, A. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30835-1 · Cited by 42
Amellal, H., Assaid, N., Charoute, H., Akarid, K., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0288557 · Cited by 46
Mazzoni, A., Vanni, A., Spinicci, M., Lamacchia, G., Kiros, S. T., Rocca, A., Capone, M., Lauria, N. D., Salvati, L., Carnasciali, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157990 · Cited by 42
Moscara, L., Venerito, V., Martinelli, A., Lorenzo, A. D., Toro, F., Violante, F. S., Tafuri, S., & Stefanizzi, P. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.043 · Cited by 40
Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective
Zhuang, C., Liu, X., Chen, Q., Yuxin, S., Su, Y., Huang, S., Wu, T., & Xia, N. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.828806 · Cited by 42
Zhao, Z., Cui, T., Huang, M., Liu, S., Su, X., Li, G., Song, T., Li, W., Zhong, N., Xu, M., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2048969 · Cited by 41
“Several studies have indicated that vaccination can only confer 6–8 months of protective immunity against severe disease and death [1,2].”
BackgroundLi, Z., Liu, S., Li, F., Li, Y., Li, Y., Peng, P., Li, S., Li, H., & Liu, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965971 · Cited by 44
“As shown in Table 2, five studies reported efficacy above 80% (54, 59, 64, 71, 73), while the remaining four showed efficacy between 50% and 70%.”
BackgroundMethodResultInfluentialFedele, G., Trentini, F., Schiavoni, I., Abrignani, S., Antonelli, G., Baldo, V., Baldovin, T., Bandera, A., Bonura, F., Clerici, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1021396 · Cited by 41
mRNA vaccines against respiratory viruses
Whitaker, J. A., Sahly, H. M. E., & Healy, C. M. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000948 · Cited by 40
“After 6months follow-up, BNT162b2 showed 91% efficacy against symptomatic COVID-19 and 97% efficacy against severe COVID-19 [10].”
BackgroundRonk, A. J., Lloyd, N. M., Zhang, M., Atyeo, C. G., Perrett, H. R., Mire, C. E., Hastie, K. M., Sanders, R. W., Brouwer, P. J. M., Saphire, E. O., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41376-6 · Cited by 41
“The mRNA vaccine platform is highly versatile and has been shown to be highly ef fi cacious against SARS-CoV-2 54,55 .”
Vass, W. B., Lednicky, J. A., Shankar, S. N., Fan, Z. H., Eiguren-Fernandez, A., & Wu, C. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4100428 · Cited by 43
Malavazos, A. E., Basilico, S., Iacobellis, G., Milani, V., Cardani, R., Boniardi, F., Dubini, C., Prandoni, I., Capitanio, G., Renna, L. V., et al. (2021) · Obesity · doi:10.1002/oby.23353 · Cited by 39
“Moreover, in a recent study, it was shown that BNT162b2 mRNA vaccine efficacy tends to gradually decrease after 6 months while maintaining a high safety profile (20).”
BackgroundPascuale, C. A., Varese, A., Ojeda, D. S., Pasinovich, M., López, L., Rossi, A. H., Rodríguez, P. E., Miglietta, E. A., Mazzitelli, I. G., García, F. D. D., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100706 · Cited by 44
“Age, years, mean (SD) 43 (11) 41 (10) 34 (8) 40 (9) 36 (20)”
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda, V. P., Jogi, G., Dave, S., Patel, B. M., Nalla, L. V., & Koradia, K. D. (2023) · Vaccines · doi:10.3390/vaccines11030507 · Cited by 42
Decru, B., Elslande, J. V., Steels, S., Pottelbergh, G. V., Godderis, L., Holm, B. V., Bossuyt, X., Weyenbergh, J. V., Maes, P., & Vermeersch, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909910 · Cited by 42
“Despite waning over time, residual humoral immunity may still be sufficient to protect against severe disease as lower amounts of neutralizing antibodies are required for protection against severe disease compared to mild infection (1, 3, 5, 11, 26).”
BackgroundInfluentialNanotechnology for the management of COVID-19 during the pandemic and in the post-pandemic era
Xu, C., Lei, C., Hosseinpour, S., Ivanovski, S., Walsh, L. J., & Khademhosseini, A. (2022) · National Science Review · doi:10.1093/nsr/nwac124 · Cited by 43
Barbeau, D. J., Martin, J. M., Carney, E., Dougherty, E., Doyle, J., Dermody, T. S., Hoberman, A., Williams, J. V., Michaels, M. G., Alcorn, J. F., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00504-x · Cited by 45
Hamm, S. R., Rezahosseini, O., Møller, D. L., Loft, J. A., Poulsen, J. R., Knudsen, J. D., Pedersen, M. S., Schønning, K., Harboe, Z. B., Rasmussen, A., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17141 · Cited by 39
Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Bertera, H. L., Chicz, T. M., Lévican, J., Poblete, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39189-8 · Cited by 39
DBPP-Predictor: a novel strategy for prediction of chemical drug-likeness based on property profiles
Gu, Y., Wang, Y., Zhu, K., Li, W., Liu, G., & Tang, Y. (2024) · Journal of Cheminformatics · doi:10.1186/s13321-024-00800-9 · Cited by 41
Megastudy shows that reminders boost vaccination but adding free rides does not
Milkman, K. L., Ellis, S. F., Gromet, D. M., Jung, Y., Luscher, A. S., Mobarak, R. S., Paxson, M. K., Zumaran, R. A. S., Kuan, R., Berman, R., et al. (2024) · Nature · doi:10.1038/s41586-024-07591-x · Cited by 47
Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting
Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 40
Higher COVID-19 Vaccination Rates Are Associated with Lower COVID-19 Mortality: A Global Analysis
Hoxha, I. S., Agahi, R., Bimbashi, A., Aliu, M., Raka, L., Bajraktari, I., Beqiri, P., & Adams, L. V. (2022) · Vaccines · doi:10.3390/vaccines11010074 · Cited by 42
“We then added a two week period, which is the amount of time required for vaccinations to take effect [6].”
BackgroundChen, R. E., Gorman, M. J., Zhu, D. Y., Carreño, J. M., Yuan, D., VanBlargan, L. A., Burdess, S., Lauffenburger, D. A., Kim, W., Turner, J. S., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.004 · Cited by 38
Long-Term Analysis of Antibodies Elicited by Sputnik V in Tucuman, Argentina
Chahla, R. E., Tomas‐Grau, R. H., Cazorla, S. I., Ploper, D., Pingitore, E. V., López, M. A., Aznar, P., Alcorta, M. E., Vélez, E. M. D. M., Stagnetto, A., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100123 · Cited by 42
Sato, S., Sano, S., Muto, H., Kubara, K., Kondo, K., Miyazaki, T., Suzuki, Y., Uemoto, Y., & Ukai, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00089 · Cited by 43
Severity of COVID-19 cases in the months of predominance of the Alpha and Delta variants
Florensa, D., Mateo, J., Spaimoc, R., Miret, C., Godoy, S., Solsona, F., & Godoy, P. (2022) · Scientific Reports · doi:10.1038/s41598-022-19125-4 · Cited by 37
Singh, A. K., Phatak, S., Singh, R., Bhattacharjee, K., Singh, N. K., Gupta, A., & Sharma, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102424 · Cited by 37
Sen, P., Ravichandran, N., Nune, A., Lilleker, J. B., Agarwal, V., Kardeş, S., Kim, M., Day, J. A., Milchert, M., Gheita, T. A., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac305 · Cited by 36
mRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 37
Metabolite, protein, and tissue dysfunction associated with COVID-19 disease severity
Rahnavard, A., Mann, B. T., Giri, A., Chatterjee, R., & Crandall, K. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-16396-9 · Cited by 39
OECD (2021) · Health at a glance · doi:10.1787/13aff239-en · Cited by 37
Covid-19 vaccination: evidence of waning immunity is overstated
Scott, J. A., Richterman, A. G., & Çevik, M. (2021) · BMJ · doi:10.1136/bmj.n2320 · Cited by 39
Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety
Meng, H., Mao, J., & Ye, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27590 · Cited by 36
Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
Sadeghalvad, M., Mansourabadi, A. H., Noori, M., Nejadghaderi, S. A., Masoomikarimi, M., Alimohammadi, M., & Rezaei, N. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2359 · Cited by 42
“351 variant.(42) Phases I and II trials of mRNA‐1273 vaccine developed by Moderna in the USA showed both humoural and cellular immune responses induction post‐vaccination.”
BackgroundClinical Efficacy of SARS-CoV-2 Vaccination in Hemodialysis Patients
Torres, R., Toro, L. G., Sanhueza, M. E., Lorca, E., Ortiz, M., Pefaur, J., Clavero, R., Machuca, E. A., González, F., Herrera, P., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.07.007 · Cited by 35
“10,11 It is highly likely that, as in the general population, 12 the most effective prevention against severe illness or death from COVID-19 in hemodialysis patients is adequate vaccination.”
Zhou, G., Dael, N., Verweij, S., Balafas, S., Mubarik, S., Oude Rengerink, K., Pasmooij, A. M. G., van Baarle, D., Mol, P. G. M., de Bock, G. H., et al. (2025) · European Respiratory Review · doi:10.1183/16000617.0222-2024 · Cited by 34
Wang, X., Cottrell, C. A., Hu, X., Ray, R., Bottermann, M., Villavicencio, P. M., Yan, Y., Xie, Z., Warner, J. E., Ellis-Pugh, J. R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn0622 · Cited by 35
“The role of lipid nanoparticle (LNP)–encapsulated nucleoside mRNA (mRNA-LNP) vaccines in combating the SARS- CoV-2 pandemic ( 45 , 46 ) has rendered them an attractive format for other infectious diseases. mRNA-LNP vaccines may overcome some challenges associated with GT: Immunogens may be produced…”
BackgroundDifferential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects
Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 37
“Although Thomas et al. shown a gradually declining trend in vaccine efficacy, spikespecific memory B cells of vaccinators persisted 6 months after vaccination, playing a crucial role in fighting against SARS-CoV2 infection (Ciabattini et al., 2021; Thomas et al., 2021).”
BackgroundThe Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 36
Laing, E. D., Weiss, C. D., Samuels, E. C., Coggins, S. A., Wang, W., Wang, R., Vassell, R. A., Sterling, S. L., Tso, M. S., Conner, T. L., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2804.212037 · Cited by 37
“Conclusions In this prospective cohort study of generally healthy, adult HCWs, we found that SARS-CoV-2 spike IgG bAbs and nAbs induced by BNT162b2 mRNA COVID-19 vaccination wane but remained detectable through 6 months after vaccination, corroborating results of another study (9).”
ResultBánki, Z., Mateus, J., Rössler, A., Schäfer, H., Bante, D., Riepler, L., Grifoni, A., Sette, A., Simon, V. R., Falkensammer, B., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104073 · Cited by 36
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
Underwood, E., Dunkle, L. M., Madhi, S. A., Gay, C. L., Heath, P. T., Kotloff, K. L., Smith, K., Chau, G., Galbiati, S., McGarry, A., et al. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2218913 · Cited by 36
Xia, H., He, Y.-R., Zhan, X.-Y., & Zha, G. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105668 · Cited by 35
Estimating SARS‐CoV‐2 infections and associated changes in COVID‐19 severity and fatality
Marziano, V., Guzzetta, G., Menegale, F., Sacco, C., Petrone, D., Mateo‐Urdiales, A., Manso, M. D., Bella, A., Fabiani, M., Vescio, M. F., et al. (2023) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13181 · Cited by 35
Porru, S., Monaco, M. G. L., Spiteri, G., Carta, A., Pezzani, M. D., Lippi, G., Gibellini, D., Tacconelli, E., Vecchia, I. D., Sala, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081193 · Cited by 36
“According to available literature, there is a persistence of protection lasting at least six months after the second dose, despite a waning of antibody titer from the vaccine second dose, for both BNT162b2 and ChAdOx1 nCoV-19 [15,20].”
BackgroundChen, Z., Shu, J., Hu, Y., & Mei, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.019 · Cited by 33
Ota, N., Itani, M., Aoki, T., Sakurai, A., Fujisawa, T., Okada, Y., Noda, K., Arakawa, Y., Tokuda, S., & Tanikawa, R. (2025) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2025.111223 · Cited by 33
“…has spurred the rapid development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines of diverse formulations. mRNA vaccines BNT162b2 (BioNTech-Pfizer) and mRNA-1273 (Moderna/NIAID) have demonstrated high efficacy and safety in clinical trials for COVID-19 prevention [1 – 3].”
InfluentialIge, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 34
Magliulo, D., Wade, S. D., & Kyttaris, V. C. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108897 · Cited by 36
CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864298 · Cited by 35
Sobieszczyk, M. E., Maaske, J., Falsey, A. R., Sproule, S., Robb, M. L., Frenck, R. W., Tieu, H., Mayer, K. H., Corey, L., Neuzil, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160565 · Cited by 36
“S (13), with a gradual decline in efficacy over time (12–15).”
Self-citationFavresse, J., Gillot, C., Bayart, J., David, C., Simon, G., Wauthier, L., Closset, M., Dogné, J., & Douxfils, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28164 · Cited by 34
Nickel, O., Rockstroh, A., Wolf, J., Landgraf, S., Kalbitz, S., Kellner, N., Borte, M., Pietsch, C., Fertey, J., Lübbert, C., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263861 · Cited by 35
“Studies suggested that SARS-CoV-2 specific antibody production following double vaccination with the BNT162b2 (BioNTech/Pfizer) mRNA vaccine is comparable to seroconversion following recovery from COVID-19 [1].”
Hsu, L., Grüne, B., Buess, M., Joisten, C., Klobucnik, J., Nießen, J., Patten, D., Wolff, A., Wiesmüller, G. A., Kossow, A., et al. (2021) · Vaccines · doi:10.3390/vaccines9111267 · Cited by 33
Kertes, J., Gez, S. B., Saciuk, Y., Supino‐Rosin, L., Shamir-Stein, N., Mizrahi-Reuveni, M., & Zohar, A. E. (2021) · Emerging infectious diseases · doi:10.3201/eid2802.211834 · Cited by 32
“In publishing third-phase research results, Pfi zer-BioNTech reported a 91% effi cacy rate over a 6-month follow-up period and an estimated 6% decrease in effi cacy every 2 months (7).”
BackgroundA Tale of Three Recent Pandemics: Influenza, HIV and SARS-CoV-2
Miranda, M., Pingarilho, M., Pimentel, V., Torneri, A., Seabra, S. G., Libin, P., & Abecasis, A. B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.889643 · Cited by 38
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Sunagar, R., Singh, A., & Kumar, S. (2023) · Vaccines · doi:10.3390/vaccines11040849 · Cited by 35
“The Pfizer BNT162b2 and Moderna mRNA-1273 COVID-19 vaccines have been shown to provide significant protective efficacy against the ancestral strain and the Alpha variant after a single dose, despite low or undetectable levels of nAbs [88,89].”
BackgroundGenetic determinants of IgG antibody response to COVID-19 vaccination
Bian, S., Guo, X., Yang, X., Wei, Y., Yang, Z., Cheng, S., Yan, J., Chen, Y., Chen, G., Du, X., et al. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.12.005 · Cited by 34
“51,52 We found a consistent pattern wherein the frequency of HLA-DRB1*13:02 progressively decreased across the African, European, and Asian ancestry groups, registering values of 7.34%, 4.85%, and 2.40%, respectively (Table S22).”
BackgroundInfluentialHafiz, I., Illian, D. N., Meila, O., Utomo, A. R. H., Susilowati, A., Susetya, I. E., Desrita, D., Siregar, G. A., & Basyuni, M. (2022) · Vaccines · doi:10.3390/vaccines10010082 · Cited by 33
“3% and has a high efficacy advantage in dealing with beta variants [36].”
BackgroundFaliti, C. E., Van, T. T. P., Anam, F. A., Cheedarla, N., Williams, M. E., Mishra, A. K., Usman, S. Y., Woodruff, M. C., Kraker, G., Runnstrom, M. C., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-02010-9 · Cited by 34
“Despite the demonstrated safety and efficacy of SARS-CoV-2 mRNA vaccines in immunocompetent individuals 1,2,13 , a full understanding of their effectiveness in immunocompromised persons is still lacking.”
Singer, S. R., Angulo, F. J., Swerdlow, D. L., McLaughlin, J. M., Hazan, I., Ginish, N., Anis, E., Mendelson, E., Mor, O., Zuckerman, N. S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101190 · Cited by 32
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Gordon, J. E., Speicher, L. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.12.002 · Cited by 34
Taus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 34
Liu, X., Mostafavi, H., Ng, W. H., Freitas, J. R., King, N. J. C., Zaid, A., Taylor, A., & Mahalingam, S. (2022) · mBio · doi:10.1128/mbio.00683-22 · Cited by 32
Freund, O., Tau, L., Weiss, T. E., Zornitzki, L., Frydman, S., Jacob, G., & Bornstein, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268050 · Cited by 31
“Booster administration was reinforced by studies showing a decline in vaccine efficacy and lower levels of neutralizing antibodies [3, 5, 6, 9].”
BackgroundXu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 32
Metadata
- Authors
- Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Yang, Q., Liberator, P., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Gruber, W. C., & Jansen, K. U.
- Affiliations
- Pfizer (United States) (US)
- From the State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., S.B., W.V.K., D.C., Q.Y., P.L., P.R.D., W.C.G., K.U.J.) — both in New York; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and iTrials-Hospital Militar Central (G.P.M.) and Fundacion INFANT, Buenos Aires (F.P.P.) — all in Brazil; Centro Paulista de Investigação Clinica, São Paulo (C.Z.); Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., X.X.) and Worldwide Safety, Safety Surveillance, and Risk Management (D.B.T., S.M.), Pfizer, Collegeville, PA; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (Ö.T., U.Ş.) and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Cent...
- Corresponding author
- Absalon, Judith
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-04
- Volume
- 385
- Issue
- 19
- Pages
- 1761-1773
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8461570
- OpenAlex
- W3200157219
- Semantic Scholar
- 1f8a398d84bc89852aee671b48f84e4363399de3
- Cited by
- 1,640
- References
- 28
- Citations by year
- 2026: 57 · 2025: 141 · 2024: 212 · 2023: 343 · 2022: 654 · 2021: 229
- FWCI
- 114.02
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2 spike protein, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, long-term follow-up, waning immunity, severe COVID-19 prevention, B.1.351 variant, emergency use authorization, children and adolescents, adverse events, trial discontinuation
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Child, Female, Follow-Up Studies, Humans, Immunization, Secondary, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.